AstraZeneca’s Iressa Produces Effect In Subpopulation, ASCO Data Show
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Results of an initial Phase II study aimed at identifying responders to AstraZeneca's non-small cell lung cancer agent Iressa suggest further research could support approval in a subpopulation, researchers said at the recent American Society of Clinical Oncology meeting in Orlando, Fla